Masters of Immunology
Yonit Lavin and Miriam Merad
Cancer Immunol Res October 1 2013 1 (4) 201-209; DOI:10.1158/2326-6066.CIR-13-0117
Using B cells from patients with chronic lymphocytic leukemia (CLL), Nakahara and colleagues have produced a lamprey monoclonal antibody with CLL idiotope specificity that can be used for early detection of leukemia recurrence. Lamprey antibodies can be generated rapidly and offer a complementary approach to the use of classical Ig-based anti-idiotope antibodies in the monitoring and management of patients with CLL.
In a retrospective study, Tang and colleagues identified an increase in ICOS+ CD4 T cells following anti-CTLA-4 therapy and proposed its use as a pharmacodynamic biomarker for anti-CTLA-4 immunotherapy.
Using archived blood samples from 4 NY-ESO-1-seropositive patients with advanced melanoma who were treated with the CTLA-4-blocking monoclonal antibody ipilimumab, Kitano and colleagues analyzed changes in antigen-specific CD4+ T cells during cancer immunotherapy. They characterized a novel consequence of the CTLA-4 blockade, the induction or expansion of tumorreactive cytotoxic CD4+ T cells after ipilimumab treatment.
Oda and colleagues show that lysophosphatidic acid (LPA) suppression of T-cell activation and proliferation is mediated by the LPA5 receptor expressed by CD8 T cells, and that LPA5-deficient CD8 T cells are more efficient in controlling the growth of established tumors in a murine melanoma model. These data suggest that LPA5 blockade may provide an additional strategy to promote tumor immunity.
Through their treatment of mouse models of human prostate cancer with the combined regimen of docetaxel and 2aG4, the mouse IgG2a version of bavituximab, a humanized antiphosphatidylserine (anti-PS)-targeting chimeric antibody (Ab) currently being tested in clinical trials for cancer, Yin and colleagues explored potential strategies by which anti-PS-targeting Ab alter the tumor microenvironment to restore tumor immunity.